Liquor Impacting Brain Activity (Credit-Freepik)
Many of us believe that we are great drinkers and that alcohol does not affect us as much. People who are able to drink without showing any sign of inebriation are known as social drinkers. In short, they are not addicted to alcohol but will not turn down the opportunity to have a good time! While it may seem like it doesn’t affect you, new studies suggest that it is just an illusion, even if you have high tolerance, alcohol affects your cognitive and motor functions more than you think.
The study reveals the below implications and techniques:
Think of it as the foundation for your brain's performance. When brain conductivity is high, information flows smoothly, and that helps your brain in rapid processing and response. On the other hand, low conductivity can hinder cognitive function, leading to slower thinking, impaired memory, and difficulties with coordination.
A study conducted at the Neuroscience Research Australia (NeuRA) and UNSW Science unveiled a startling connection between alcohol consumption and brain conductivity.
While many people brush off the effects of alcohol as temporary changes in behaviour, the reality is much more complex. Beyond the obvious impacts on coordination and judgment, alcohol significantly alters brain function. Alcohol dramatically slowed down brain activity, especially in areas responsible for decision-making, planning, and physical coordination. This decline was so significant that it resembled the brain changes seen in normal ageing. This means even one drink could temporarily accelerate the ageing process of your brain.
The implications of this research are far-reaching. It provides compelling evidence that alcohol consumption has a direct and measurable impact on brain function. The discovery that alcohol can significantly reduce brain conductivity opens new avenues for understanding the neurocognitive effects of alcohol abuse and dependence. While you may not feel like alcohol is affecting you and you have a high tolerance, it most definitely changes and affects your decision-making abilities and impulse control.
Furthermore, the MRI technique employed in the study could be a valuable tool for assessing the impact of other substances on the brain and for developing interventions to mitigate alcohol-related brain damage.
Credit: iStock
The XFG COVID-19 variant is driving a rise in cases and hospitalizations in the UK and France, while some US regions are also reporting increases.
XFG, nicknamed ‘American COVID’ or Stratus, is a recombinant SARS-CoV-2 variant from the Omicron lineage, formed from LF.7 and LP.8.1.2. The WHO recorded the earliest documented XFG sample on January 27, 2025, and designated it a variant under monitoring in June 2025.
The NHS has advised infected people to stay home to limit spread. The UK is rolling out COVID vaccination, while France is expected to begin its campaign next week.
COVID and flu symptoms can overlap, including cough, fever, sore throat, headache, runny nose and fatigue.
In France, the estimated number of people with COVID consulting GPs for acute respiratory infections rose to 13 per 100,000, from nine the previous week, according to The Connexion. This translates to around 8,806 new cases, up from about 6,000.
In England, hospital PCR positivity rose from 5.9% to 7.0% in the week to September 20, while hospital admissions increased from 0.81 to 1.20 per 100,000. Overall activity remained low.
US CDC data from September 29 showed cases rising in some states while falling or remaining stable in others.
Also read: ‘American Covid’ Strain Drives 50% Surge in UK Hospital Admissions: XFG Symptoms to Know
HealthandMe spoke to experts who said the UK-France rise does not necessarily mean India will see a similar increase.
“The rise in COVID-19 cases in the UK and France does not necessarily mean that India is headed towards a similar increase,” said Dr Suranjit Chatterjee, Senior Consultant, Internal Medicine, Indraprastha Apollo Hospitals, Delhi.
XFG is being monitored because it has become more common in some countries, but available evidence does not indicate that it causes more severe illness than other circulating variants.
“For India, the more relevant question is whether XFG is increasing locally and whether this is translating into a rise in symptoms or hospitalizations,” Dr Suranjit told HealthandMe .
Dr Amit Prakash Singh, Consultant - Internal Medicine, CK Birla Hospital, Delhi, said the spread of XFG highlights the need for continued surveillance as SARS-CoV-2 evolves.
“Yet at present there is no evidence to indicate that the XFG variant causes more severe disease than the other Omicron-lineage variants,” he said.
However, the “main concern for India would be a greater rate of transmission, especially among older people, those with comorbidities and the immunocompromised, should the variant become more common in the country”.
Read More: COVID-19 Cases Rise In France, Vaccination Campaign Set To Start Next Week
Dr Amit told HealthandMe India should continue genomic surveillance and monitor hospitalizations and severe disease rather than focusing only on case numbers.
Dr Suranjit said international travel can introduce new variants, but their impact depends on community spread and existing immunity.
“At this stage, there is no reason for people (in India) to be unduly concerned or change their daily routine.”
He added that continued surveillance, timely testing when symptoms occur and sensible precautions during respiratory infections remain appropriate.
XFG-specific vaccines have been developed and are either in use or authorized in several countries. The US and UK have opted for XFG-targeted formulations for the 2026–27 season.
In India, an XFG-specific vaccine should be considered available only after regulatory approval and commercial supply.
The WHO continues to stress that vaccination should not be postponed while waiting for an updated formulation.
Credit: AI
Canada has determined to restrict medical assistance in dying (MAID) for patients whose sole underlying condition is a mental illness, shelving plans to expand the eligibility in 2027.
Justice Minister Sean Fraser said the government will introduce legislation to maintain the exclusion beyond the current deadline of March 17, 2027.
The decision comes weeks after an Ontario court rejected a woman's request for an exemption that could have allowed her to seek MAID because of severe, longstanding mental illness.
The government says there is still no sufficient medical consensus on when a mental illness can be considered irremediable, a key requirement under Canada's MAID policy.
Fraser said, “When I hear that there is a lack of consensus within the medical community about the irremediable nature of certain mental illnesses, that gives me real cause for concern.” He also pointed out that access to mental health care in the country is uneven.
He acknowledged that the issue does not have unanimous agreement but defended the government's decision. “While there is not a perfect consensus on this issue, we believe this is the correct approach at this particular time,” Fraser said.
Canada had originally kept the exception as temporary. When MAID eligibility was expanded in 2021 to people whose natural death was not reasonably foreseeable, mental illness as the sole underlying condition that was deemed ineligible.
The exclusion was subsequently delayed several times, with March 2027 becoming the latest planned date for possible expansion.
Also read: Canadian Parliamentary Panel Urges Indefinite Ban on Assisted Dying for Mental Illness Alone
The announcement comes just after a controversial case involving Claire Elyse Brosseau, a 49-year-old Toronto woman who sought a constitutional exemption from the existing MAID exclusion.
Brosseau said she has lived with severe mental-health problems for decades and had undergone multiple forms of treatment. In May, she asked the Ontario Superior Court for emergency relief that would allow her to apply for MAID.
On September 3, Justice Carissima Mathen rejected that request. She also ordered the federal government to respond to Brosseau's constitutional challenge to the exclusion.
Mathen described Brosseau's evidence of suffering as credible and compelling, but said the case also involved Parliament's role in making decisions on “sensitive social issues” and interpreting the Charter rights involved.
Brosseau, meanwhile, said the decision was nothing but another barrier for people with mental illness. “It is yet another example of governmental systems telling people with mental illnesses that we do not have the same rights nor the same autonomy as others,” she said.
The government's decision also follows a recommendation that was passed in June from a joint parliamentary committee, which called to exclude people from MAID eligibility whose only underlying condition is mental illness.
The committee's review highlighted disagreements among experts over whether clinicians can reliably determine that certain mental illnesses are permanently irremediable.
It was based on a report that noted a "divergence of perspectives" on the issue and highlighted concerns raised during testimony about the "pressing need for increased and more equitable access to adequate mental health services".
However, the recommendation was not unanimous. Four senators issued a dismissed the report, questioning the committee's process, arguing that the government should consider seeking guidance from the Supreme Court of Canada.
Also read: New York Assisted Suicide Law: Nearly 20 People Reportedly Died Since August
The government's proposed legislation is expected to circle back to advance requests, which is another another debatable aspect of MAID.
Under the proposed changes, people diagnosed with serious illnesses who may eventually lose the ability to consent could be able to make an advance request for MAID.
According to the latest available figures from 2024, MAID accounts for around 5 per cent of all deaths in Canada. About 96 per cent of MAID cases involved people whose deaths were reasonably foreseeable, most of them terminal cancer patients.
The remaining 4 per cent involved patients whose deaths were not imminent but who had a "grievous and irremediable medical condition".
Credit: AI
The Supreme Court, on Thursday, asked the Centre to form a panel to form statutory regulations against unethical practices by pharmaceutical companies. This includes gift giving, hospitality, and other incentives offered to doctors.
A bench of Justices Vikram Nath and Sandeep Mehta issued the direction while hearing a petition seeking stronger regulation of pharmaceutical marketing practices.
The court wants the committee to recommend whether, and how, the unethical interactions between pharmaceutical companies and doctors should be brought under a legally enforceable framework.
The matter will resume in court on January 29, 2027, when the Centre is expected to show compliance with the directions.
The court's order follows earlier concerns about whether the existing system is equipped to prevent unethical pharmaceutical marketing.
Justice Sandeep Mehta, reading out the order, said, “We have directed the Union of India to constitute the committee and give its recommendations in terms of our previous directives and observations.”
The committee will examine the representations received and make recommendations to the Union government on the need for statutory regulation.
The Court had reserved order after Solicitor General Tushar Mehta informed the Court that the Union government is to form a three-member committee to assess whether a statutory framework is needed to regulate unethical practices by pharmaceutical companies.
The case was filed by the Federation of Medical and Sales Representatives' Associations of India (FMRAI), which has sought accountability for alleged practices such as expensive gifts, foreign trips, hospitality and other benefits used to promote medicines to doctors.
It said, “This has led to over-prescription of drugs resulting in a serious infringement of the right to life and the right to health of the citizens.”
Also read: Russia Denies Second Plague Case As WHO Seeks Answers On Lab Death; Trump Says It’s Not A Bioweapon
Pharmaceutical companies use various marketing strategies to promote their products to healthcare professionals. These can include gifts, hospitality, sponsored travel, benefits related to conference and other promotional incentives.
The concern before the Supreme Court is not just an ordinary interaction between drug companies and doctors, but whether financial or material incentives can unethically influence drug-prescribing decisions.
India already has the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), 2024, which lays down rules concerning gifts, physician samples, brand reminders, continuing medical education and other promotional activities. However, questions remain over whether the framework has adequate statutory regulation.
The Centre has previously said the UCPMP is functioning, but agreed that the question of giving pharmaceutical marketing regulation statutory backing should be examined separately.
The Centre, in its response, said, “The Department of Pharmaceuticals has issued the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which is applicable to Pharmaceutical Companies, medical representatives and agents.” The code clearly prohibits pharmaceutical companies from offering gifts, travel facilities, hospitality, cash or monetary grants to physicians or their family members, it added.
The biggest concern is that a prescribing decision could become influenced by factors other than clinical need, evidence, safety, and cost. If incentives influence prescribing, patients could potentially face:
These concerns have previously been raised before the Supreme Court in relation to alleged pharmaceutical marketing practices. The issue, therefore, goes beyond ethics for patients. The doctor-pharma relationship can directly affect what medicine a patient receives, how long they take it, and how much they pay.
© $2026 Times Horizon Private Limited